Highlights Biohaven Ltd.

Equities

BHVN

VGG1110E1079

End-of-day quote Nyse Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
37.08 ^USD	-0.43%		-10.35%	-13.36%

May. 15	Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	MT
May. 14	Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	May. 10	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Biohaven Prices $230 Million Public Share Offering	Apr. 18	MT
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	Feb. 29	MT
Biohaven Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Biohaven Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Biohaven Pharmaceutical Q3 Net Loss Narrows	Nov. 14	MT
Biohaven Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®	23-10-16	CI
Biohaven Completes Enrollment in Spinal Muscular Atrophy Phase 3 Study of Taldefgrobep Alfa	23-09-14	MT
Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies	23-09-05	CI
Biohaven Narrows Q2 Non-GAAP Loss; Gets Orphan Drug Label for Taldefgrobep Alfa in Europe	23-07-31	MT
Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Pfizer CEO calls US drug price plan 'negotiation with a gun to your head'	23-05-11	RE
Biohaven Purchases License to Develop BHV-8000 for Treatment of Immune-Mediated Brain Disorders	23-03-22	MT
Biohaven Granted US FDA Fast Track Designation for Spinal Muscular Atrophy Treatment Candidate	23-02-21	MT
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy	23-02-21	CI
Drug companies face COVID cliff in 2023 as sales set to plummet	23-02-06	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biohaven Ltd.

Equities

BHVN

VGG1110E1079

Highlights

Filters